Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity.

Journal Article (Journal Article)

Guidelines on managing infants after initial anti-vascular endothelial growth factor (VEGF) treatment (eg, bevacizumab) for retinopathy of prematurity (ROP) are limited. We found that following initial bevacizumab treatment for ROP, prophylactically lasering infant eyes before hospital discharge reduced the number and duration of outpatient ROP screening examinations compared with following infants, per current United States (US) ROP screening guidelines.

Full Text

Duke Authors

Cited Authors

  • Hong, GJ; Stinnett, SS; Freedman, SF; Wallace, DK; Prakalapakorn, SG

Published Date

  • June 2021

Published In

Volume / Issue

  • 25 / 3

Start / End Page

  • 177 - 180

PubMed ID

  • 33964453

Electronic International Standard Serial Number (EISSN)

  • 1528-3933

Digital Object Identifier (DOI)

  • 10.1016/j.jaapos.2021.02.002


  • eng

Conference Location

  • United States